RAPT Therapeutics Inc (RAPT) Stock
RAPT is no longer traded. RAPT Therapeutics was acquired by GSK in March 2026.
Each RAPT share was exchanged for $58.00 in cash. Prices on this page are historical; the last trade was March 2, 2026 at $58.01.
See GSK stock →RAPT Therapeutics stock price history
RAPT final trading statistics
- Final close
- $58.01
- Final trading day
- Mar 2, 2026
- Market cap at delisting
- $1.68B
- Shares outstanding
- 28.96M
- Final 52-week range
- $0.71 – $58.01
- Avg. volume (final 3 mo.)
- 2,373,786
- All-time high (split-adj.)
- $390.88 · Jan 2020
- All-time low (split-adj.)
- $5.98 · May 2025
- Return since IPO
- -44.2%
- Beta
- 0.44
- Book value / share
- $9.02
- Price / book
- 6.43
RAPT Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | -$129.9M | -$3.19 |
| FY2023 | $0.00 | -$116.8M | -$3.04 |
| FY2022 | $1.53M | -$81.9M | -$2.58 |
| FY2021 | $3.81M | -$68.2M | -$2.53 |
| FY2020 | $5.04M | -$52.9M | -$2.19 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About RAPT Therapeutics Inc
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company.
RAPT Therapeutics stock FAQ
What happened to RAPT Therapeutics stock?
RAPT Therapeutics was acquired by GSK in March 2026. Shareholders received $58.00 in cash for each share. RAPT stock stopped trading on the Nasdaq, with a final close of $58.01 on March 2, 2026.
What did RAPT Therapeutics shareholders receive?
Each RAPT share was converted into $58.00 in cash. The deal was valued at about $2.2 billion.
Is RAPT stock still trading?
No. RAPT was delisted from the Nasdaq in March 2026 and no longer trades on a U.S. exchange.
What was the last price of RAPT stock?
RAPT closed at $58.01 on its final trading day, March 2, 2026, for a market value of about $1.68B.
What were RAPT Therapeutics's revenue and earnings in its last full fiscal year?
RAPT Therapeutics reported revenue of $0.00 and net income of -$129.9M in fiscal 2024, its last full year as a public company.
When did RAPT Therapeutics go public?
RAPT Therapeutics Inc stock began trading on October 31, 2019.